NEW YORK (TheStreet) -- Drugmaker AstraZeneca(AZN_) said Monday a Phase III study of zibotentan monotherapy in patients with prostate cancer will be stopped since the drug is unlikely to meet its endpoints of progression free survival and overall survival.
